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The published literature comparing surgery, with or without adjuvant endocrine therapy, with endocrine therapy alone in older
women with operable breast cancer was systematically reviewed.The design used is Cochrane review. Randomised controlled trials
retrieved from the Cochrane Breast Cancer Group Specialised Register on 29 June 2005. Eligible studies recruited women aged 70
years or over with operable breast cancer, fit for surgery under general anaesthia. The studies compared surgery (either mastectomy
or wide local excision, with or without endocrine therapy) to endocrine therapy alone. Primary outcomes were overall survival (OS)
and progression-free survival (PFS). Double data extraction and quality assessment were undertaken. Seven eligible trials were
identified of which six had published time-to-event data. The quality of the allocation concealment was adequate in three studies and
unclear in the remainder. In each case the endocrine therapy used was tamoxifen. When surgery alone was compared to endocrine
therapy alone, there was no significant difference in OS (hazard ratio (HR) 0.98, 95% confidence interval (CI) 0.74–1.30, P¼0.9), but
a significant difference in PFS (HR 0.55, 95% CI 0.39–0.77, P¼0.0006). When surgery with adjuvant endocrine therapy was
compared to endocrine therapy alone, there was no significant difference in OS (HR 0.86, 95% CI 0.73–1.00, P¼0.06), but a
significant difference in PFS (HR 0.65 (95% CI 0.53–0.81, P¼0.0001) for surgery plus endocrine therapy vs primary endocrine. The
regimens have different side effect profiles with one study suggesting increased psychosocial morbidity at 3 months in the surgical
arm, which resolves by 2 years. Primary endocrine therapy with tamoxifen is associated with inferior local disease control but non-
inferior survival to surgery for breast cancer in older women. Trials are needed to evaluate appropriate selection criteria for its use in
terms of patient co-morbidity and quality of life. Trials are needed to evaluate the clinical effectiveness of aromatase inhibitors as
primary therapy for this population.
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The standard treatment for early-stage breast cancer in women of
all ages was surgery until the late 1970s (Kesseler and Seton, 1978).
Primary endocrine therapy was first described in the early 1980s as
an alternative for older women (Preece et al, 1982). Treatment
involved the sole use of tamoxifen, an oestrogen-receptor
antagonist, without surgery, radiotherapy or chemotherapy.
Tamoxifen is effective in around 80% of women with moderately
or strongly ER-positive tumours (Gaskell et al, 1992), but the
duration of local disease control is shorter than with surgery, and
some women require either alternate endocrine therapies or
surgery at a later date (Kenny et al, 1998).
In the UK, the trend towards treating women aged 70 and over
with tamoxifen alone has been based on the premise that they are
less likely to be fit for surgery because of co-morbidity (Satariano
and Ragland, 1994). However, both mastectomy and wide local
excision have low mortality rates (Hunt et al, 1980; Wyld and Reed,
2003). Breast surgery-related morbidity, especially where axillary
surgery is involved, is quite high and may impact on quality of life.
Primary endocrine therapy is not a treatment option in the USA
and is rarely used in Australia (Craft et al, 2000; Diab et al, 2000).
In the UK, its use is widespread, with up to 42% of all women over
70 being treated in this way, regardless of whether co-morbidity is
documented (Wyld et al, 2004).
To establish whether primary endocrine therapy is justifiable for
women who are fit for surgery, we systematically reviewed the
evidence from randomised trials comparing primary endocrine
therapy to surgery, with or without adjuvant endocrine therapy, in
the management of women aged 70 years or over with operable
breast cancer.
METHODS
Full details of the methods employed are published elsewhere
(Hind et al, 2006). The Cochrane Breast Cancer Group Specialised
Register was searched on 29 June 2005. Citations coded as ‘EARLY
BREAST CANCER’, ‘ENDOCRINE THERAPY’, ‘PSYCHOSOCIAL’
or ‘SURGERY’ on the specialised register were retrieved with no
date or language restrictions.
Only controlled trials with the following characteristics were
included. Participants were women aged 70 years or over with
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sclinically defined operable primary breast cancer: TNM classifica-
tion T1-3 and T4b where there was only minor skin involvement,
N0-1, mobile lymph nodes (Union Internationale Contre le Cancer,
1987). Studies had to compare either (1) surgery alone vs primary
endocrine therapy; or (2) surgery plus adjuvant endocrine therapy
vs primary endocrine therapy. Mastectomy could be with or
without axillary clearance, and wide local excision could be with or
without radiotherapy. Primary outcomes were overall survival
(OS) and progression-free survival (PFS) (interval between start of
treatment and need for second-line or palliative treatment,
recurrence or death from any cause). Secondary outcomes were
adverse effects (number of surgical complications or endocrine
therapy related side effects), local disease control (interval between
start of treatment and the development of local disease), distant
metastasis-free interval (interval between start of treatment and
the development of metastatic disease) and quality of life (however
measured). Pre-specified subgroups included the type of surgery
(mastectomy or wide local excision, with or without radiotherapy).
Two reviewers, LW and DH, independently assessed each
potentially eligible trial for inclusion in the review with the results
section masked. The same two reviewers independently reviewed
each study according to its design and by how the study was
conducted to assess any bias. The checklist for quality of
randomised controlled trials included: concealment of the alloca-
tion sequence, generation of the allocation sequence, compar-
ability between groups at the baseline and inclusion of all
randomised participants in the analysis. For allocation conceal-
ment, trials were graded ‘A’ (adequate concealment), ‘B’ (adequacy
of concealment unclear) or ‘C’ (clearly inadequate concealment).
The most complete data set feasible was assembled from the
published literature. Where necessary, we sought additional
information from the principal investigator of the trial concerned.
Results of eligible studies were statistically synthesised if appro-
priate and possible. For time-to-event analyses, combined hazard
ratios (HRs) and 95% confidence intervals (CIs) were estimated
using formal methods for extracting summary statistics to perform
meta-analyses of the published literature (Parmar et al, 1998).
Heterogeneity between trial results was tested using the w
2 test and
the I
2 measurement (Higgins et al, 2003). Absolute risk reductions
and numbers needed to treat were calculated using the Altman and
Andersen (1999) method.
RESULTS
The search strategy retrieved 770 citations. Of these, 742 were
excluded based on information in the title or abstract. The
remaining 28 citations reported on the seven potentially eligible
studies for the review. None of these studies was excluded. Five
additional papers, all conference abstracts, relating to the same
trials were identified through informal reference tracking and
contact with authors. The study selection process is illustrated in
Figure 1, in accordance with the QUOROM statement (Moher et al,
1999).
Three eligible trials addressing surgery vs primary tamoxifen
therapy were identified (Table 1), all of which reported outcome
data (Gazet et al, 1994; Kenny et al, 1998; Fentiman et al, 2003).
None of the studies evaluated the oestrogen receptor status of the
women they recruited. Four eligible trials addressing surgery plus
endocrine therapy vs primary endocrine therapy were identified, of
which three have reported outcome data (Willsher et al, 1997;
Capasso et al, 2000; Mustacchi et al, 2003; Fennessey et al, 2004),
although there is currently no data from one in a form that can be
meta-analysed (Capasso et al, 2000). Not all trials identified
provided adequate information on all outcomes. Only one of the
studies evaluated oestrogen receptor status, recruiting only women
with moderately or strongly oestrogen receptor-positive tumours
(Willsher et al, 1997).
It was not possible to assess accurately the quality of all studies
(including the quality of the randomisation process) owing to lack
of information in the published articles. The quality of three trials
was graded as A (Fentiman et al, 2003; Mustacchi et al, 2003;
Fennessey et al, 2004) with the rest being graded as B (Gazet et al,
1994; Willsher et al, 1997; Kenny et al, 1998; Capasso et al, 2000).
No potentially eligible study was excluded from the review.
Proposed sensitivity analysis based on trial quality was not
conducted because of the small number of trials identified. There
was good agreement on study selection, quality assessment, and
data extraction.
Results are presented in Table 2. Analysis of OS, based on three
trials (495 women: Gazet et al, 1994; Kenny et al, 1998; Fentiman
et al, 2003), showed no significant difference between interven-
tions (HR 0.98, 95% CI 0.74–1.30, P¼0.9). One trial (164 women:
Fentiman et al, 2003) reported adequate summary data to show a
significant difference in PFS, favouring surgery (HR 0.55, 95% CI
0.39–0.77, P¼0.0006). In the surgery arm, 77% of women had
died or progressed compared to 84% in the tamoxifen arm: an
extra 7% of participants receiving surgery benefited from the
treatment. For every 14 women treated, one death or disease
progression would be prevented over 120 months.
Methodological issues (discussed below) prohibited either the
meta-analysis of, or dissemination of results from the three trials,
which reported data on local disease control or the distant
metastasis-free interval. One trial (200 women: Gazet et al, 1994)
reported adverse events. No patient discontinued primary
tamoxifen treatment. Eight patients had a total of 10 side effects,
including hot flushes, skin rash, vaginal discharge, indigestion,
breast pain, and sleepiness. No trial reported quality of life data.
Results are presented in Table 3. Three trials (1076 women:
Willsher et al, 1997; Mustacchi et al, 2003; Fennessey et al, 2004)
reported data on OS which could be meta-analysed. There was a
nonsignificant trend in favour of surgery plus endocrine therapy
(HR 0.86, 95% CI 0.73–1.00, P¼0.06). Only one trial (474 women:
Mustacchi et al, 2003) reported adequate data on PFS to calculate a
significant difference favouring surgery plus endocrine therapy
(HR 0.65, 95% CI 0.53–0.81, P¼0.0001). In the surgery arm, 59%
of women died or progressed compared to 80% in the tamoxifen
Citations identified through the
electronic search strategy,
reference tracking or contact
with trialists
n=775
Citations included in the review
n=33
(relating to seven controlled trials)
Citations excluded on the basis of
information in the title or abstract
n=742
Studies incorporated in the
meta-analyses
n=6
Study excluded from the
meta-analyses (Naples study:
inadequate data)
n=1
Figure 1 QUOROM flow diagram showing study selection process.
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sarm: an extra 21% of participants receiving surgery benefited from
the treatment. For every five women treated, one death or disease
progression would be prevented over 80 months.
Analysis of two trials (929 women: Mustacchi et al, 2003;
Fennessey et al, 2004) showed a significant difference in local
disease control in favour of surgery plus endocrine therapy (HR
0.28, 95% CI 0.23–0.35, Po 0.00001). There was significant
heterogeneity between the two studies (w
2 2.90, Po0.09, I
2 65.6%),
which is discussed below, although each individually showed a
statistically significant difference in treatment effect favouring the
surgery arm. Data from one trial (Willsher et al, 1997) were not
included in this analysis as reported results were immature
Table 1 Study characteristics
Study Participants Interventions Outcomes
Allocation
concealment
EORTC 10851 (UK) n¼164
(Fentiman et al, 2003)
Women (aged 70+) with operable
breast cancer
Surgery (mastectomy; full axillary
clearance) vs tamoxifen
(20mgday
 1)
Survival - overall; PFS; local disease
control; distant metastasis free
survival
A
Nottingham 1 (UK) n¼131
(Kenny et al, 1998)
Women (aged 70+) with operable
breast cancer
Surgery (wedge mastectomy;
limited axillary surgery) vs
tamoxifen (40mgday
 1)
Survival - overall; PFS; local disease
control; distant metastasis free
survival
B
St Georges (UK) n¼200
(Gazet et al, 1994)
Women (aged 70+) with operable
breast cancer
Surgery (mastectomy or wide local
excision without radiotherapy;
axillary surgery not specified) vs
tamoxifen (20mgday
 1)
Survival - overall; PFS; local disease
control; distant metastasis free
survival
B
CRC (UK) n¼455 (Fennessey
et al, 2004)
Women (aged 70+) with operable
breast cancer
Surgery (mastectomy or wide local
excision without radiotherapy;
axillary surgery not specified) plus
tamoxifen (40mgday
 1) vs
tamoxifen alone
Survival - overall; PFS; local disease
control; distant metastasis free
survival; psychiatric and social
morbidity
A
GRETA (Italy) n¼274
(Mustacchi et al, 2003)
Women (aged 70+) with operable
breast cancer
Surgery (mastectomy or wide local
excision with radiotherapy; axillary
clearance) plus tamoxifen
(20mgday
 1) vs tamoxifen alone
Survival - overall; PFS; local disease
control; distant metastasis free
survival
A
Naples (Italy) n¼75 (Capasso
et al, 2000)
Women (aged 70+) with operable
breast cancer
Surgery (mastectomy or wide local
excision with
radiotherapy;7axillary clearance)
plus tamoxifen (20mgday
 1) vs
tamoxifen alone
Survival - overall; PFS B
Nottingham 2 (UK) n¼147
(Willsher et al, 1997)
Women (aged 70+) with operable
breast cancer
Surgery (wedge mastectomy;
limited axillary surgery) plus
tamoxifen vs tamoxifen
(20mgday
 1)
Survival - overall; PFS B
PFS¼progression-free survival. Surgery vs primary endocrine therapy.
Table 2 Surgery vs primary endocrine therapy results
Trial Median follow-up Surgery n/N Primary endocrine therapy n/N HR (95% CI)
Surgery primary endocrine therapy
Mortality (‘OS’)
EORTC 10851 10 years 60/82 50/82 1.11 (0.75–1.65)
Nottingham 1 5 years 28/65 28/66 1.06 (0.59–1.92)
St Georges 6 years 28/100 33/100 0.75 (0.44–1.26)
Mortality, recurrence or progression (‘PFS’)
EORTC 10851 10 years 63/82 69/82 0.55 (0.39–0.77)
Nottingham 1 12 years 56/65 57/66 Not estimable
St Georges 6 years 60/100
a 70/100
a Not estimable
Local recurrence or local progression as first event
EORTC 10851 10 years 7/82 47/82 Not calculated
b
Nottingham 1 9 years 16/65
a 45/66
a Not calculated
b
St Georges 6 years 36/100 53/100 Not calculated
b
Distant metastases as first or simultaneous event
EORTC 10851 10 years 15/82 7/82 Not calculated
b
Nottingham 1 12 years NR NR Not calculated
b
St Georges 6 years 14/100 8/100 Not calculated
b
OS¼overall survival; PFS¼progression-free survival.
aIndividual patient data from trial list.
bNot calculated because of 20–50% competing risks (Nottingham 1 and EORTC
10851) and informative censoring (St Georges). Surgery plus adjuvant endocrine therapy vs primary endocrine therapy.
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scompared to the other two studies. Adequate data were not
available to evaluate the difference in distant metastasis-free
interval. One study reported that both mastectomy and wide local
excision significantly improved local control compared to primary
endocrine therapy (Fennessey et al, 2004).
One trial did not quantify adverse events, only reporting that one
woman from the primary endocrine therapy arm had to drop out of
the trial because of endocrine therapy-related adverse effects
(Fennessey et al, 2004). In another, all patients in the surgery plus
tamoxifen arm who had axillary clearance had paraesthesia on the
ipsilateral arm and lateral thoracic wall. Tamoxifen-related toxicity
was similar between the two arms and included headache, vertigo,
itching, hair loss, cystitis, vaginal bleeding, acute thrombophlebitis,
nausea, and indigestion (Mustacchi et al, 2003). The other two
studies did not report adverse events (Willsher et al, 1997; Capasso
et al, 2000). No trial investigated differences in quality of life.
The only trial to evaluate differences in psychiatric morbidity
(CRC) used the General Health Questionnaire 28 (Goldberg et al,
1970), and a socio-demographic questionnaire, which investigated
levels of domestic support and social isolation. At 3 months after
the start of treatment the surgery group had more psychosocial
morbidity (P¼0.03); however, there was no difference between the
surgery and primary endocrine therapy groups at 2 years
(Fallowfield, 1994).
DISCUSSION
Statement of principal findings
This study has demonstrated that primary endocrine therapy is
inferior to surgery with endocrine therapy for the local control of
breast cancer in ER-unselected, medically fit older women. This is
independent of the type of surgery, with both mastectomy and
wide excision (without adjuvant radiotherapy) achieving superior
local control. The meta-analysis showed no significant difference
in OS between the two treatments in this group of women. One
trial showed a small but significant survival advantage for surgery
with adjuvant endocrine therapy, where follow-up was extended to
13 years (Fennessey et al, 2004). There are no data on formal QoL
assessments between these two groups and no data on patients’
preferences.
Strengths and weaknesses of the study
The results of this review are based on a limited number of small
studies of variable methodological quality. In some cases, the
internal validity of the primary studies was affected by competing
risks and informative censoring, which violate the assumptions
underlying the Kaplan–Meier survival analysis method (these
issues are discussed fully elsewhere in Hind et al, 2006).
Heterogeneity between trials, in terms of interventions and
outcome assessment, also made assessment of some outcomes
problematic. There was considerable variation in surgical techni-
que to the breast and the axilla (Table 1). It was unclear whether
surgical margins were adequate by modern standards in any trial.
In one trial, case selection for breast conservation included women
with large tumours (T3 and T4) which would be inappropriate by
modern standards (Gazet et al, 1994). Two of the trials which
offered women wide local excision (St Georges and CRC) did not
report using adjuvant radiotherapy which is standard practice
today and may have reduced the clinical effect size of surgery
(Gazet et al, 1994; Fennessey et al, 2004). In the analysis of local
disease control in the second comparison (surgery with adjuvant
tamoxifen vs primary tamoxifen) statistical heterogeneity cannot
be explained by differences in population or treatment character-
istics and is likely to be an artefact of the CRC trial’s longer follow-
up time.
Most trials recruited women regardless of oestrogen receptor
status. Only 85–90% of women in this age group have ER-positive
tumours (Diab et al, 2000). For the remainder, tamoxifen is not
an active intervention and their treatment with tamoxifen is
not therefore in line with modern clinical practice. The inclusion
of such women may also have biased the results of the meta-
analysis. Had such women been excluded from included trials,
the primary endocrine therapy arms may have performed
better against surgery arm plus endocrine therapy. However, the
one trial to recruit exclusively patients with ER-positive tumours
found local control to be superior with surgery and endocrine
therapy (Willsher et al, 1997). Furthermore, none of the included
studies controlled for patient co-morbidity and even among
those fit for surgery in this age group, a significant propor-
tion of patients will die of co-morbid diseases so reducing the
relative advantages of any breast cancer therapies (Satariano and
Ragland, 1994).
Table 3 Surgery plus adjuvant endocrine therapy vs primary endocrine therapy results
Trial Median Follow up Surgery n/N Primary endocrine therapy n/N HR (95% CI)
Surgery plus endocrine therapy vs primary endocrine therapy
Mortality (‘OS’)
CRC 13 years 159/225 187/230 0.78 (0.63–0.96)
GRETA 7 years 130/239 144/235 0.98 (0.77–1.25)
Nottingham 2 5 years 8/53 14/94 0.80 (0.73–2.32)
Mortality or progression (‘PFS’)
CRC 13 Years NR NR NR
GRETA 7 years 140/239 188/235 0.65 (0.53–0.81)
Nottingham 2 5 years NR NR NR
Local recurrence or local progression as first event
CRC 13 years 36/225 115/230 0.25 (0.19–0.32)
GRETA 7 years 27/239 95/235 0.38 (0.25–0.57)
Nottingham 2 3 years 2/53 30/94 Not estimable
Distant metastases as first or simultaneous event
CRC 13 years 20/225 14/235 Not estimable
GRETA 7 years 0/225 10/235 Not estimable
Nottingham 2 3 years NR NR Not estimable
Surgery and tamoxifen for older women with breast cancer
D Hind et al
1028
British Journal of Cancer (2007) 96(7), 1025–1029 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sStrengths and weaknesses in relation to other studies
This is the first systematic review on this topic and provides an
overview of all primary studies on the subject.
Meaning of the study possible explanations and
implications for clinicians and policymakers
Primary endocrine therapy should only be offered to women with
ER-positive tumours who are unfit for, or who refuse, surgery. In a
cohort of women with reduced life expectancy, owing to significant
co-morbid disease, and ER-positive tumours, primary endocrine
therapy may be an appropriate treatment choice. A national UK
trial will shortly be starting to evaluate selection criteria for the use
of primary endocrine therapy, (Endocrine þ/  Surgical Therapy
for Elderly women with Mammary cancer, ESTEEM), which will
aid in decision making.
Unanswered questions and future research
Since these studies were designed, endocrine therapies other than
tamoxifen have become available. Aromatase inhibitors have been
shown to be superior to tamoxifen in the adjuvant setting and may
by attractive as primary endocrine therapy for older women who
are unfit for surgery. Trials are needed to test this hypothesis. The
ESTEEM trial will use aromatase inhibitors rather than tamoxifen,
which may enhance the efficacy of primary endocrine therapy.
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